When is neoadjuvant chemotherapy indicated in the treatment of breast cancer?

Updated: May 21, 2019
  • Author: Erin V Newton, MD; Chief Editor: Neetu Radhakrishnan, MD  more...
  • Print


The best candidates for neoadjuvant chemotherapy are patients with ER-negative and/or HER2-positive expressing tumors whose pathologically complete response (pCR) rates can approach 65% and predict long-term survival. Patients with ER-positive, HER2-negative locally advanced breast cancer (LABC) are unlikely to achieve a pCR from currently available chemotherapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!